Gina Mauro


FDA Approves Naxitamab-gqgk for Relapsed/Refractory High-Risk Neuroblastoma

November 25th 2020

The FDA has approved naxitamab-gqgk (Danyelza) for use in combination with granulocyte-macrophage colony-stimulating factor as a treatment for pediatric patients 1 year of age and older and adult patients with relapsed/refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior treatment.

Selinexor Improves PFS in Advanced Unresectable Dedifferentiated Liposarcoma

November 25th 2020

Selinexor demonstrated a statistically significant improvement in progression-free survival compared with matching placebo in patients with advanced unresectable dedifferentiated liposarcoma, following at least 2 prior treatments.

SIENDO Trial of Selinexor in Endometrial Cancer Gets Green Light to Continue

November 25th 2020

The phase 3 SIENDO study, which is evaluating maintenance selinexor in endometrial cancer, has been recommended by the Data and Safety Monitoring Board to continue as previously planned without the need to add additional patients to the trial or amend the study protocol, following a prespecified interim futility analysis.

Nivolumab Approved in Europe for Advanced Esophageal Cancer

November 24th 2020

November 24, 2020 - The European Commission has approved nivolumab for the treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma following prior fluoropyrimidine- and platinum-based combination chemotherapy.

Devimistat Granted Orphan Drug Status for Soft Tissue Sarcoma 

November 24th 2020

November 24, 2020 — The FDA has granted an orphan drug designation to devimistat for the treatment of patients with soft tissue sarcoma.

NCCN Grants Category 2A Recommendation to Decitabine/Cedazuridine Combo for MDS

November 23rd 2020

November 23, 2020 - The National Comprehensive Cancer Network has updated its Clinical Practice Guidelines in Oncology for Myelodysplastic Syndromes (MDS) to include the combination of decitabine and cedazuridine as a category 2a recommendation for the treatment of adult patients with intermediate- and high-risk MDS.

Tebentafusp Improves OS in Frontline Metastatic Uveal Melanoma

November 23rd 2020

November 23, 2020 - Tebentafusp showed superiority in overall survival compared with investigator’s choice of therapy in patients with previously untreated metastatic uveal melanoma.

Maintenance Niraparib, Given at Individualized Starting Dose, Improves PFS in Chinese Patients With Ovarian Cancer

November 21st 2020

November 21, 2020 — Maintenance niraparib, when administered at an individualized starting dose, led to a 70% reduction in the risk of disease progression or death compared with placebo in Chinese patients with recurrent ovarian cancer who were in a complete or partial response to platinum-based chemotherapy.

Moffitt Expert Emphasizes Need to Improve Sarcoma Diagnoses

November 19th 2020

Marilyn M. Bui, MD, PhD, highlights the importance of pathology in sarcoma and how it is the cornerstone of precision medicine.

Plinabulin/Pegfilgrastim Combo Reduces Rate of Chemotherapy-Induced Neutropenia

November 16th 2020

November 16, 2020 - The combination of plinabulin and pegfilgrastim showed a statistically significant improvement in the rate of prevention of grade 4 neutropenia versus pegfilgrastim alone in patients with cancer undergoing chemotherapy.